However, we believe that the PD field will benefit from our lead compounds by enabling new potential avenues for research and drug development that have, until now, been impeded by the many off-targets and the toxicity of commercially available type-II LRRK2 inhibitors. The gene discussed is LRRK2; the disease is Parkinson disease.